Skip to content
Companies

Conexeu Sciences

Flowable collagen scaffold for wound repair

Raised to date

$2.1M

of $3.9M offered across 9 Form D filings

Still open
$1.8M
Investors
1
Last filed
Jul 31, 2026

About

Conexeu Sciences Inc. is a preclinical-stage regenerative tissue platform company headquartered in Reno, Nevada, with R&D operations in Vancouver. It develops collagen-based extracellular matrix (ECM) technology, branded CXU, that is delivered as a room-temperature flowable liquid and transitions in situ to a gel-like scaffold at body temperature in roughly ten minutes, providing temporary structure for the body to repopulate, remodel and regenerate its own tissue. The technology came out of more than a decade of university research and is being advanced toward wound care first, with a 510(k) premarket notification planned for early 2027. The company began trading on Nasdaq under the ticker CNXU in May 2026.

A patented biomimetic ECM that is injectable or printable as a flowable liquid and self-gels at body temperature, making one collagen scaffold platform addressable across wound care, aesthetics, oral health, veterinary use and 3D bioprinting rather than a single fixed-form implant.

Funding

$1.8M, first sold Mar 2026$1.8M soldJun 2025DecJun 2026
Now
  • EquityFiled Jul 31, 2026Form D
    $63K/ $63K
  • EquityFiled Jun 30, 2026Form D
    $86K/ $86K
  • Security to be acquiredFiled Jun 30, 2026Form D
    $203/ $466K
  • EquityFiled Jun 12, 2026Form D/A
    $2K/ $2K
  • EquityFiled Jun 10, 2026Form D
    $23K/ $137K
  • EquityFiled May 21, 2026Form D
    $45K/ $45K
  • Security to be acquiredFiled May 21, 2026Form D
    $543/ $1.2M
  • EquityFiled Apr 1, 2026Form D
    $1.8M/ $1.8M
  • EquityFiled Mar 23, 2026Form D
    $45K/ $45K

Product

CXU

Regenerative medical device (preclinical)

A patented biomimetic collagen extracellular matrix scaffold, marketed as Ten Minute Tissue, delivered as a room-temperature flowable gel that converts in situ to a structural matrix at body temperature to support natural tissue regeneration. It is an investigational medical device candidate in preclinical development and has not been cleared by the FDA.

  • Flowable at room temperature, gels in situ in about ten minutes at body temperature
  • Biomimetic collagen extracellular matrix architecture
  • Three-phase mechanism: repopulation, remodeling, regeneration

Built for

Clinicians and health systems treating complex wounds, plus aesthetic, reconstructive, dental and veterinary practitioners once cleared

People on file